INS and fatty liver disease: Emerging evidence suggests that these agents may also confer hepatoprotective effects through multiple mechanisms including reduction of hepatic steatosis and fibrosis, improvement in insulin sensitivity, anti‐inflammatory actions, and modulation of the gut‐liver axis [6, 7, 8].